Audience
HCP panel (US)
HCP (US): a public Ask Brox audience of Brox clones, each built from a long-form interview with a real person. Every insight fielded on this panel, newest first.
What did the HCP panel say?
- #
65.2%
65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine — Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
base 198
- #
55.1%
55.1% (109 of 198) would rely on an AI-generated one-page summary of a newly approved medicine's pivotal trial, a 5 or more of 7, when every number links to the exact line of the published paper it comes from, against 0 of 198 when it shows no sources and 72.7% (144 of 198) when a named independent physician has also checked it against the paper. — AI summaries of a new drug's trial: 0 of 198 US physicians and other prescribers would rely on one with no sources, 55.1% when every number links to the paper and 72.7% once a named physician has checked it
base 198
- #
66.7%
Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. — Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
base 198
- #
58.6%
58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. — Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points
base 169
- #
73.2%
73.2% of US clinicians would ignore the manufacturer's email first when a medicine they already prescribe gains a new indication, more than any other channel; nobody picked a colleague, a conference, or a journal as the one to ignore. — New indication news: 73% of US clinicians, mostly dermatologists, would ignore the manufacturer's email first, and none would read more than three promotional emails a month
base 198
What has Brox published on hcp panel (us)?Newest first
-
Medical science liaisons: 60.1% of US physicians and other prescribers want real-world and subgroup evidence for patients like theirs, and 65.2% rate a liaison meeting useful against 17.7% for a sales rep
65.2% 65.2% rate a 20-minute meeting with a medical science liaison at least moderately useful to their practice, against 17.7% for a 20-minute meeting with a sales representative about the same kind of medicine (base 198)
Read -
AI summaries of a new drug's trial: 0 of 198 US physicians and other prescribers would rely on one with no sources, 55.1% when every number links to the paper and 72.7% once a named physician has checked it
55.1% 55.1% (109 of 198) would rely on an AI-generated one-page summary of a newly approved medicine's pivotal trial, a 5 or more of 7, when every number links to the exact line of the published paper it comes from, against 0 of 198 when it shows no sources and 72.7% (144 of 198) when a named independent physician has also checked it against the paper. (base 198)
Read -
Pharma rep visits: 66.7% of US clinicians, mostly dermatologists, would turn away a rep who asks to come every two weeks, against 39.4% for a monthly visit
66.7% Asked by a rep for a medicine they already prescribe for a 10-minute in-person visit, 66.2% of US clinicians would agree to one every three months, 58.1% to one a month and 31.8% to one every two weeks; the share who would decline rises from 30.8% to 39.4% to 66.7%. (base 198)
Read -
Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points
58.6% 58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60. (base 169)
Read -
New indication news: 73% of US clinicians, mostly dermatologists, would ignore the manufacturer's email first, and none would read more than three promotional emails a month
73.2% 73.2% of US clinicians would ignore the manufacturer's email first when a medicine they already prescribe gains a new indication, more than any other channel; nobody picked a colleague, a conference, or a journal as the one to ignore. (base 198)
Read -
Only 2 of 173 US physicians discount pharmaceutical promotion because AI wrote it, while 63% discount content no expert has reviewed
2 Almost nobody objects to AI writing the content. They object to nobody checking it. (base 173)
Read -
Generic or brand? A $15 a month gap is enough for 89% of US clinicians, mostly dermatologists, to write the generic when a patient asks for the brand
88.9% 88.9% of US clinicians would prescribe the generic, after explaining the saving, when a patient asks for the brand and the brand costs the patient $15 a month more; at a $50 gap it is 98.5% and at $150 it is 99.0% (base 198)
Read -
Prior authorization, not the evidence, is what delays 14 of 18 US oncologists from prescribing a new first-line cancer regimen
14 14 of 18 US oncologists say prior authorization or coverage denials most often delay their first prescription of a newly approved first-line regimen; none named unfamiliar side effects or a formulary review. (base 18)
Read -
Adult ADHD with anxiety: the ten US physicians who manage it do not refer, and six treat the anxiety first
6 Not one of the ten physicians who manage this patient refers it straight out. (base 10)
Read -
Biosimilar substitution: 94.5% of US clinicians, mostly dermatologists, accept a switch they choose, but half object when a pharmacy swaps without contacting them
50% 50.0% of physicians who manage biologics are uncomfortable (1 or 2 of 5) with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them first, against 2.7% when they choose the switch and 20.5% when an insurer requires it. (base 146)
Read
What do people ask about hcp panel (us)?
- What do physicians want from a medical science liaison that a sales rep cannot give them?
- Real-world and subgroup evidence for patients like their own: 60.1% of US physicians and other prescribers on the Brox HCP panel name it as what they most want from a medical science liaison that a sales rep cannot give, and 65.2% rate a 20-minute liaison meeting at least moderately useful against 17.7% for a rep meeting (n=198, November 2026).Read the insight
- Would a physician trust an AI summary of a new drug's trial data over the label or a rep?
- Over the rep but not the label: 55.1% of US physicians and other prescribers on the Brox panel would rely on an AI summary of a new medicine's pivotal trial when every number links to the published paper, none would rely on one with no sources, and 66.2% would ignore the sales rep first against 24.2% the AI summary and 0% the FDA label (n=198, November 2026).Read the insight
- What makes a doctor stop seeing pharma reps altogether?
- Being asked too often, and their employer: 66.7% of US clinicians on the Brox HCP panel would decline a 10-minute pharma rep visit every two weeks against 39.4% monthly, and 24 of the 36 who no longer see reps name a practice or health system restriction (n=198, November 2026).Read the insight
- What does a physician need to see before switching a stable patient to a newer therapy, and how much better does it have to be?
- 58.6% of US clinicians on the Brox panel would keep a patient who has been stable for two years on their current therapy even when a newer one gets 15 more patients in 100 to the treatment goal at the same cost and with similar safety, and 32.5% would still keep them at 30 more (n=169, October 2026).Read the insight
- How do clinicians want to hear about a new indication for a medicine they already prescribe, and which channel actually changes what they prescribe?
- When a medicine they already prescribe gains a new FDA-approved indication, 73.2% of US clinicians on the Brox panel would ignore the manufacturer's email about it first, and 71.7% would rather hear first from a colleague, a conference, or a journal (n=198, October 2026).Read the insight
- What share of physicians discount pharmaceutical promotional content because AI was involved in writing it?
- Only 2 of 173 US physicians on the Brox panel would discount pharmaceutical promotional content because AI was involved in writing it, while 63% say they begin discounting it when no expert has reviewed it (n=173, October 2026).Read the insight
- How do physicians decide between a generic and a branded medicine when both are on formulary?
- When a patient asks for the brand and their plan covers both versions, 88.9% of US clinicians on the Brox panel would prescribe the generic once the brand costs the patient $15 a month more (n=198, October 2026).Read the insight
- What makes an oncologist adopt a newly approved first-line cancer therapy straight away, rather than wait for guidelines, payer coverage or peers?
- 14 of 18 US oncologists in the Brox HCP panel say prior authorization or coverage denials, not the trial data or the guideline listing, are what most often delay their first prescription of a newly approved first-line cancer regimen (n=18, October 2026).Read the insight
- When an adult patient has ADHD alongside significant anxiety, what does a US physician do first, and what would change it?
- Of the ten US physicians on the panel who manage adult ADHD with comorbid anxiety, none refers the patient straight out: six treat the anxiety first, and nine said evidence that one daily medicine improved both conditions would make them treat the ADHD themselves (September 2026).Read the insight
- How do physicians feel about biosimilar substitution, and where do they push back?
- Half of US physicians who manage biologics (50.0%, n=146, September 2026) are uncomfortable with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them, against 2.7% when they choose the switch themselves.Read the insight
Other audiences
- Anime Fans (US) 4
- Brox HNWI (US) 8
- Casual dining and restaurants (US) 2
- E-commerce (US) 7
- Finance (US) 5
- G.B. nat. rep. (GB) 14
- GLP-1 (US) 1
- GLP-1 Considerers (US) 2
- GLP-1 Past Users (US) 3
- Groceries (US) 3
- HCP Dermatologists (US) 4
- HCP Other (Non-Derm) (US) 2
- Healthcare (US) 10
- Healthcare Professionals (US) 1
- HNWI (VC/Tech) (US) 3
- Insurance (US) 15
- Investing (US) 1
- Japan nat. rep. (JP) 1
- Music (US) 1
- Streaming (JP) 1
- Streaming (US) 16
- Streaming (TR) 1
- Streaming - Custom (US) 2
- Tech (US) 5
- Tech (GB) 1
- Travel (US) 6
- TV & Social Media (JP) 1
- U.S. nat. rep. (US) 102
How should you read these findings?
Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.
Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.
What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.
Ask this of your own customers: humans@brox.ai